A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Key Inclusion Criteria:

1. All patients must be either stage IIB, IIC, III, or stage IV per American JointCommittee on Cancer (AJCC) 8th edition and have histologically confirmed melanomathat is completely surgically resected in order to be eligible as defined by theprotocol

2. Complete surgical resection must be performed within 12 weeks prior torandomization, and enrollment may occur only after satisfactory wound healing fromthe surgery

3. All patients must have disease-free status documented by a complete physicalexamination and imaging studies within 4 weeks prior to randomization, as describedin the protocol

Key Exclusion Criteria:

1. Uveal melanoma

2. Any evidence of residual disease after surgery by imaging, pathology, or cytology.

3. Ongoing or recent (within 2 years) evidence of clinically significant autoimmunedisease that required treatment

4. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C (HCV) infection; or diagnosis of immunodeficiency that isrelated to, or results in chronic infection, as described in the protocol

5. Another malignancy that is currently progressing or that required active treatmentin the past 5 years, as described in the protocol

6. Participants with a history of myocarditis

7. Adolescent patients (≥12 to <18 years old) with body weight <40 kg

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply